Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia

Journal of Clinical Psychopharmacology

Volumn 18, Issue 2, 1998, Pages 103-110

  Nair, N P Vasavan ^a,b   Reiner, C ^c   Reiter Schmitt, B ^c   Ronovsky, K ^c   Vyssoki, D ^c   Baeke, J ^c   Desseilles, M ^c   Kindts, P ^c   Mesotten, F ^c   Peuskens, J ^c   Addington, D ^c   Baruch, P ^c   Beauclair, L ^c   Bloom, D ^c   Bouchard, R H ^c   Filteau, M ^c   Jeffries, J ^c   Jones, B ^c   Labelle, A ^c   Major, B ^c   Nair, N ^c   Pourcher, E ^c   Remington, G ^c   Ripley, C ^c   Toews, J ^c   Vincent, P ^c   Wolf, M ^c   Zipursky, R ^c   Chabannes, J M ^c   Cohen, C ^c   Dupuy, C ^c   Laghrissi Thode, F ^c   Lombertie, E ^c   Lunacek, S ^c   Pagnon, I ^c   Pupeschi, G ^c   Van Amerongen, A ^c   Demling, J ^c   Ebert, D ^c   Hummel, M M ^c   Mayer, G ^c   Retterath, P ^c   Seifert, G ^c   Wennhold, B ^c   Zinztsch, I ^c   Del Zompo, M ^c   Ardon, J ^c   Dries, P ^c   Meuldijk, R ^c   Jeppesen, I ^c   Mahnfeldt, M ^c   Nerdrum, T ^c   Osby, U ^c   more..

^a MCGILL UNIVERSITY   (Canada)

^b DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; PALIPERIDONE; PLACEBO; RISPERIDONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPERKINESIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPERTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SOMNOLENCE; VOMITING;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; THERAPEUTIC EQUIVALENCY;

EID: 7144222759     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199804000-00002     Document Type: Article

References (16)

1. 2 antagonistic properties. J Pharmacol Exp Ther 1988;244: 685-93.
2. Leysen JE, Gommeren W, Eens A, De Chaffoy de Courcelles D, Stoof JC, Janssen PAJ. The biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988;247:661-70.
3. Heylen SLE, Gelders YG. Risperidone versus haloperidol in the treatment of psychotic subjects: an 8-week multicenter double-blind comparative trial [abstract 93]. Presented at the International Symposium on Serotonin, From Cell Biology to Pharmacology and Therapeutics. Florence: 1989.
4. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, Heylen S. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative trial. Acta Psychiatr Scand 1992;85:295-305.
5. Borison RL, Pathiraja A, Bruce I, Diamond BI, Meibach RC. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28:213-8.
6. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W. A Canadian multicentre placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-39.
7. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am Psychiatry 1994;151:825-35.
8. Peuskens J and the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712-26.
9. Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen A, Zylicz Z, Visscher H, Jonkman J. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993;54:257-68.
10. Kissling W, Kane J, Barnes TRE. Guidelines for neuroleptic relapse prevention in schizophrenia: towards a consensus view. In: Kissling W, ed. Guidelines for neuroleptic relapse prevention in schizophrenia. Berlin: Springer-Verlag, 1991.
11. Heykants J, Huang M-L, Mannens G, Meuldermans W, Snoek E, Van Beijsterveldt L, Van Peer A, Woestenborghs R. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994;55[suppl 5]:13-7.
12. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
13. Guy W, ed. ECDEU assessment manual for psychopharmacology. Rev. ed. Rockville, MD: National Institute of Mental Health, 1976.
14. Overall JF, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799-812.
15. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. The extrapyramidal symptom rating scale. Can J Neurol Sci 1980;7:233.
16. Blackwelder WC. Proving the null hypothesis in clinical trials. Control Clin Trials 1982;3:345-53.